Although trastuzumab improves outcomes in patients with HER2-positive breast cancer (BC) (46), trastuzumab-induced cardiotoxicity (TIC) compromises the health-related quality of life and overall survival of cancer patients (47, 48). Here, ERBB2 is linked to cancer.